Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 1 May 2012

Pelttari Hanna, Schalin-Jäntti Camilla, Arola Johanna, Löyttyniemi Eliisa, Knuutila Sakari, Välimäki Matti J

Abstract excerpt

The BRAF V600E mutation may serve as a marker of disease recurrence in well-differentiated papillary thyroid cancer (PTC). Our aim was to study if TNM stage I or II PTC patients, with and without recurrence after long-term follow-up would differ in BRAF status. BRAF status was retrospectively determined in tumour tissue from a cohort of low-risk PTC patients (n = 461) with and without recurrence after 16 years of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Follow-Up Studies

Share to Logistic Models

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 22515292
DOI: 10.1111/j.1600-0463.2011.02844.x

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients.PMID 22515292Read ↗

Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid CancerSemantic proximity Read ↗

The <i>BRAF</i> mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinomaSemantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.Semantic proximity Read ↗

BRAFV600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence.Semantic proximity Read ↗

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Semantic proximity Read ↗

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceSemantic proximity Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic FactorsSemantic proximity Read ↗

Response to therapy of papillary thyroid cancer of known BRAF status.Semantic proximity Read ↗

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.Semantic proximity Read ↗

A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.